Navigation Links
Predicting successful outcomes in living-donor liver transplants

A new study on identifying which patients were likely to have poor outcomes following a living-donor liver transplant (LDLT) found that measuring how a certain non-toxic dye was eliminated by the liver shortly after surgery was an accurate indicator of liver function, and therefore a reliable indicator of the outcome of the procedure. The study used a simple non-invasive device to measure the dye, making it particularly useful in treating transplant patients.

The results of this study appear in the April 2006 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/livertransplantation.

Monitoring liver function following LDLT is crucial and identifying poor function as early as possible would be a step in the right direction toward achieving better outcomes. Since tests traditionally used to measure liver function are not always conclusive, researchers led by Tomohide Hori of Mie University in Tsu City, Japan analyzed how indocyanine green (ICG), a non-toxic dye, was processed by the liver, assessed a non-invasive method of measuring its levels, and determined whether such a test would be a reliable indicator of outcome.

The study involved 30 adult recipients who underwent LDLT between June 2003 and February 2005 at Mie University Hospital. The patients were divided into two groups based on liver function and outcome following the transplant (as measured by traditional methods such as bilirubin concentration). Group I consisted of 24 recipients who had good clinical outcomes while group II consisted of 6 recipients who needed intensive clinical management and had poor clin ical outcomes. ICG was injected into the patients and its disappearance was monitored by a non-invasive photometric device. This was done for the first 14 days following transplant (including every 12 hours in the first 72 hours) and again at 21 and 28 days following surgery.

The results showed that immediately following transplant, elimination of ICG improved for all patients in the study when compared to pre-operative tests, but within 24 hours ICG elimination was significantly better in Group I than in Group II. The test correlated well with more traditional methods of measuring liver function, specifically liver biopsies that were performed in 17 of the patients and liver scintigraphy (an imaging technique using a radioactive substance that is swallowed) performed on 18 patients. The ICG test however, had certain benefits. "This novel noninvasive method has advantages in its simplicity, its real-time presentation of results without consuming a lot of time, and its cost-effectiveness," the researchers note. They conclude that being able to predict poor outcomes based on ICG elimination immediately following liver transplants should have a large impact on further improving LDLT outcomes, since appropriate clinical management can then be instituted if necessary.

In another study in the same issue, researchers led by Christoph Jochum, M.D. of the University Duisberg-Essen in Essen, Germany investigated ICG elimination, galactose elimination capacity (GEC), and lidocaine elimination as markers for the quality of liver regeneration in 22 donors and their recipients in the first 3 months following LDLT. They found that ICG elimination and GEC remained significantly altered in donors and improved significantly in recipients during that period, while lidocaine elimination showed no significant changes. "In this study we evaluated only a small group of patients, however the results indicate a longer and more profound change in the quality of the liver of d onors and recipients after LDLT than conventional liver function tests indicate," the authors conclude.

In an accompanying editorial, Jürg Reichen, M.D., of the University Hospital, University of Berne in Switzerland notes that ICG clearance as measured in the first study can predict poor outcomes and might be useful for LDLT recipients, while the second study points out that liver regeneration might not be complete for donors, even though the liver achieves its full size within four weeks of transplant. "Whether the about 10 percent loss of function compared to preoperative values will translate into clinically relevant impairment of liver function ?in particular with respect to drug metabolism as suggested by the authors ?has yet to be determined," he states. He also notes that the multiple blood sampling used by the second study is quite labor intensive when compared to the device used in the first study, which is more apt to make its way into clinical practice. He concludes: "Before clinical decisions are based upon any of these tests, however, confirmation of the findings in larger patient populations in prospective studies are needed."


'"/>

Source:John Wiley & Sons, Inc.


Related biology news :

1. Predicting success
2. Predicting chemotherapy outcome
3. New, automated tool successfully classifies and relates proteins in unprecedented way
4. Biomarkers isolated from saliva successfully predict oral and breast cancer
5. UN successfully tests green pesticide against locusts
6. Stem cell therapy successfully treats heart attack in animals
7. Mad cow proteins successfully detected in blood
8. Israeli scientists successfully transplant frozen-thawed ovaries in sheep
9. Magnetic probe successfully tracks implanted cells in cancer patients
10. New research examines genetics of successful aging
11. Cancer virus protein needed for successful infection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology: